188 results on '"Cheville, John C"'
Search Results
2. Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer.
- Author
-
Shah, Paras, Taylor, William R., Negaard, Brianna J., Gochanour, Benjamin R., Mahoney, Douglas W., Then, Sara S., Devens, Mary E., Foote, Patrick H., Doering, Karen A., Burger, Kelli N., Nikolai, Brandon, Kaiser, Michael W., Allawi, Hatim T., Cheville, John C., Kisiel, John B., and Gettman, Matthew T.
- Subjects
PROSTATE cancer patients ,GENETIC markers ,PROSTATE-specific antigen ,PROSTATE biopsy ,DNA methylation - Abstract
Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76% (50–92%) for csPCa (Gleason ≥ 7). At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59% (33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+). Conclusions: MDMs assayed in urine offer high sensitivity and specificity for detection of clinically significant prostate cancer. Prospective evaluation is necessary to estimate discrimination of patients as first-line screening and as an adjunct to prostate-specific antigen (PSA) testing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.
- Author
-
Pezeshki, Abdulmohammad, Cheville, John C., Florio, Angela B., Leibovich, Bradley C., and Vasmatzis, George
- Subjects
IMMUNE checkpoint inhibitors ,IMMUNE response ,TUMOR-infiltrating immune cells ,RENAL cancer ,T cells - Abstract
Background: Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response. Methods: We developed an "immunotumoroid" cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy. Immunotumoroids were developed from surgically resected renal cell carcinomas and bladder carcinomas selected for high tumor-infiltrating lymphocytes (TILs) and survived more than a month without media exchange. Immunohistochemistry was used to detect immune and nonimmune cells in cryopreserved source tumors and the resulting immunotumoroids. Immunotumoroid response to ICIs (nivolumab, pembrolizumab, and durvalumab) and chemotherapy (cisplatin, gemcitabine, and paclitaxel) was monitored in real-time with Cytotox Red staining in an Incucyte device, and the immunotumoroid response was compared to retrospective clinical drug responses. Results: Six of the 13 cases tested grew viable immunotumoroid models, with failed cases attributed to extensive tumor tissue necrosis or excess lymphocytes preventing spheroid formation. One successfully cultured case was excluded from the study due to low TIL infiltration (<5%) in the primary tumor sample. The five remaining models contained immune cells (CD4+ and CD8+ T cells, and macrophages), non-immune cells (fibroblasts), and tumor cells. Chemotherapy and ICI drugs were tested in immunotumoroids from 5 cases and compared to clinical outcomes where data was available. Four/five models showed cell killing in response to chemotherapy and two/five showed sensitivity to ICI. In three cases, the immunotumoroid model accurately predicted the patient's clinical response or non-response to ICIs or chemotherapy. Conclusion: Our immunotumoroid model replicated the multicellular nature of the tumor microenvironment sufficiently for preclinical ICI screening. This model could enable valuable insights into the complex interactions between cancer cells, the immune system, and the microenvironment. This is a feasibility study on a small number of cases, and additional studies with larger case numbers are required including correlation with clinical response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Metastatic clear cell papillary renal cell 'tumour'.
- Author
-
Gupta, Sounak, Dasari, Surendra, Sharma, Vidit, Atwell, Thomas D, Sivasankaran, Gopinath, Smoley, Stephanie A, Hardcastle, Jayson J, Lohse, Christine M, Tekin, Burak, Jimenez, Rafael E, Thompson, R Houston, Boorjian, Stephen A, Leibovich, Bradley C, and Cheville, John C
- Subjects
TUMORS ,METASTASIS ,SINGLE nucleotide polymorphisms ,RENAL cell carcinoma - Abstract
The article discusses the classification and characteristics of clear cell papillary renal cell tumours (CCPRCT). The recent World Health Organization (WHO) classification changed the nomenclature of these tumours to emphasize their indolent clinical behavior. The article presents a case study of a patient with a metastatic CCPRCT and compares the primary and metastatic tumors. The authors argue that the change in nomenclature may lead to unnecessary expensive testing and suggest reverting to the original terminology. They also highlight the need for further studies to determine the clinical impact of distinguishing CCPRCT from other renal cell carcinomas. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior.
- Author
-
Gupta, Sounak, Sholl, Lynette M, Yang, Yiying, Osunkoya, Adeboye O, Gordetsky, Jennifer B, Cornejo, Kristine M, Michalova, Kvetoslava, Maclean, Fiona, Dvindenko, Eugénia, Snuderl, Matija, Hirsch, Michelle S, Anderson, William J, Rowsey, Ross A, Jimenez, Rafael E, Cheville, John C, Sadow, Peter M, Colecchia, Maurizio, Ricci, Costantino, Ulbright, Thomas M, and Berney, Daniel M
- Subjects
GENOMICS ,OLDER men ,TUMORS ,DNA sequencing - Abstract
Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty‐seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non‐metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate‐sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS/RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non‐metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS/RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ‐related germ cell tumors rather than non‐germ cell neoplasia in situ‐derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell Carcinoma.
- Author
-
Pessoa, Rodrigo Rodrigues, Nabavizadeh, Reza, Quevedo, Fernando, Joyce, Daniel D., Lohse, Christine M., Sharma, Vidit, Costello, Brian A., Boorjian, Stephen A., Thompson, R. Houston, Leibovich, Bradley C., and Cheville, John C.
- Published
- 2023
- Full Text
- View/download PDF
7. Proteomic and Clinicopathologic Assessment of Penile Amyloidosis: A Single Institutional Review of 12 Cases.
- Author
-
Tekin, Burak, Gilani, Sarwat I, Dasari, Surendra, Theis, Jason D, Rech, Karen L, Dao, Linda N, Cubilla, Antonio L, Hernandez, Loren P Herrera, Jimenez, Rafael E, Cheville, John C, Dispenzieri, Angela, Howard, Matthew T, McPhail, Ellen D, Erickson, Lori A, Guo, Ruifeng, and Gupta, Sounak
- Subjects
PROTEOMICS ,TANDEM mass spectrometry ,LIQUID chromatography-mass spectrometry ,AMYLOIDOSIS ,CLINICAL pathology ,SURGICAL pathology - Abstract
Objectives There is a paucity of data on penile amyloidosis. We aimed to assess the frequency of different amyloid types in surgical specimens from the penis involved by amyloidosis and correlate relevant clinicopathologic parameters with proteomic findings. Methods Since 2008, our reference laboratory has performed liquid chromatography/tandem mass spectrometry (LC-MS/MS) for amyloid typing. The institutional pathology archive and reference laboratory database were queried to retrospectively identify all penile surgical pathology specimens with LC-MS/MS results between January 1, 2008, and November 23, 2022. Archived H&E-stained and Congo red–stained sections were re-reviewed. Results Twelve cases of penile amyloidosis were identified, which represented 0.35% (n = 3,456) of penile surgical specimens. AL-type amyloid was most frequent (n = 7), followed by keratin-type amyloid (n = 3) and ATTR (transthyretin)–type amyloid (n = 2). AL-type amyloid cases often showed diffuse dermal/lamina propria deposition, whereas all keratin-type amyloid cases were localized to the superficial dermis. Two cases with keratin-type amyloid had concomitant cutaneous findings (penile intraepithelial neoplasia and condyloma). Conclusions This series, the largest to date, demonstrates that penile amyloidosis has a heterogeneous proteomic landscape. To the best of our knowledge, this is the first study describing ATTR (transthyretin)–type penile amyloid. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Infrared spectroscopic laser scanning confocal microscopy for whole-slide chemical imaging.
- Author
-
Yeh, Kevin, Sharma, Ishaan, Falahkheirkhah, Kianoush, Confer, Matthew P., Orr, Andres C., Liu, Yen-Ting, Phal, Yamuna, Ho, Ruo-Jing, Mehta, Manu, Bhargava, Ankita, Mei, Wenyan, Cheng, Georgina, Cheville, John C., and Bhargava, Rohit
- Subjects
IMAGING systems in chemistry ,INFRARED lasers ,CONFOCAL microscopy ,CHEMICAL microscopy ,INFRARED microscopy ,SIGNAL-to-noise ratio - Abstract
Chemical imaging, especially mid-infrared spectroscopic microscopy, enables label-free biomedical analyses while achieving expansive molecular sensitivity. However, its slow speed and poor image quality impede widespread adoption. We present a microscope that provides high-throughput recording, low noise, and high spatial resolution where the bottom-up design of its optical train facilitates dual-axis galvo laser scanning of a diffraction-limited focal point over large areas using custom, compound, infinity-corrected refractive objectives. We demonstrate whole-slide, speckle-free imaging in ~3 min per discrete wavelength at 10× magnification (2 μm/pixel) and high-resolution capability with its 20× counterpart (1 μm/pixel), both offering spatial quality at theoretical limits while maintaining high signal-to-noise ratios (>100:1). The data quality enables applications of modern machine learning and capabilities not previously feasible – 3D reconstructions using serial sections, comprehensive assessments of whole model organisms, and histological assessments of disease in time comparable to clinical workflows. Distinct from conventional approaches that focus on morphological investigations or immunostaining techniques, this development makes label-free imaging of minimally processed tissue practical. Chemical imaging, including infrared spectroscopic microscopy with molecular sensitivity, is useful for label-free biomedical analyses, but is limited by slow speed and poor image quality. Here, the authors design a fast mid-infrared microscope with low noise and high spatial resolution for high-throughput imaging of whole slides. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer.
- Author
-
El Khoury, Louis Y, Lin, Wan Hsin, Smadbeck, James B, Barrett, Michael T, Sadeghian, Dorsay, McCune, Alexa F, Karagouga, Giannoula, Cheville, John C, Harris, Faye R, Kinsella, Lindsey M, Feathers, Ryan W, Schafer Klein, Janet L, Walther-Antonio, Marina RS, Johnson, Sarah H, Penheiter, Alan R, Cucinella, Giuseppe, Schivardi, Gabriella, Bhagwate, Aditya, Borad, Mitesh J, and Mansfield, Aaron S
- Published
- 2023
- Full Text
- View/download PDF
10. An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS).
- Author
-
Parwani, Anil V., Patel, Ankush, Ming Zhou, Cheville, John C., Tizhoosh, Hamid, Humphrey, Peter, Reuter, Victor E., and True, Lawrence D.
- Subjects
DEEP learning ,ITERATIVE learning control ,PATHOLOGY ,IMAGE analysis ,MACHINE learning - Abstract
Machine learning has been leveraged for image analysis applications throughout a multitude of subspecialties. This position paper provides a perspective on the evolutionary trajectory of practical deep learning tools for genitourinary pathology through evaluating the most recent iterations of such algorithmic devices. Deep learning tools for genitourinary pathology demonstrate potential to enhance prognostic and predictive capacity for tumor assessment including grading, staging, and subtype identification, yet limitations in data availability, regulation, and standardization have stymied their implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Chest wall resection for breast cancer: 21st century Mayo clinic experience.
- Author
-
Durgan, Diane M., De La Cruz Ku, Gabriel, Thomas, Mathew, Pockaj, Barbara A., McLaughlin, Sarah A., Casey, William J., Vijayasekaran, Aparna, Wigle, Dennis, Cheville, John C., Tonneson, Jennifer, Hoskin, Tanya L., and Jakub, James W.
- Published
- 2022
- Full Text
- View/download PDF
12. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
- Author
-
Mahmoud, Ahmed M., Frank, Igor, Orme, Jacob J., Lavoie, Roxane R., Thapa, Prabin, Costello, Brian A., Cheville, John C., Gupta, Sounak, Dong, Haidong, and Lucien, Fabrice
- Abstract
Introduction and Objectives: PD-L1 and B7-H3 have been found to be overexpressed in urothelial carcinoma (UC) of the urinary bladder. Recent studies have also demonstrated that B7-H3 and PD-L1 can promote resistance to platinum-based drugs but the predictive value of B7-H3 expression in patients treated with platinum-based chemotherapy is unknown. This study aims to investigate the association of PD-L1 and B7-H3 tumor expression with oncological outcomes in patients who underwent radical cystectomy (RC) and received subsequent adjuvant chemotherapy.Materials and Methods: Immunohistochemistry was performed on paraffin-embedded sections from bladder and lymph node specimens of 81 patients who had RC for bladder cancer. PD-L1 and B7-H3 expression on tumor cells was assessed by immunohistochemistry in both primary tumors and lymph node specimens. Association with clinicopathologic outcomes was determined using Fisher's exact test and postoperative survival using Kaplan-Meier survival curves and Cox regression model.Results: B7-H3 expression in cystectomy specimens was more common than PD-L1 expression (72.8% vs. 35.8%). For both markers, no association was found with pathologic tumor stage, lymph node (LN) status, and histological subtype. Similar findings were observed for double-positive tumors (PD-L1+B7-H3+). Concordance between the primary tumor and patient-matched lymph nodes was found in 76.2% and 54.1% of patients for PD-L1 and B7-H3, respectively. PD-L1 tumor expression was not associated with oncologic outcomes. However, B7-H3 expression was associated with recurrence-free survival (HR: 2.38, 95% CI 1.06-5.31, p = 0.035) and cancer-specific survival (HR: 2.67, 95% CI 1.18-6.04, p = 0.019).Conclusions: In our single institutional study, B7-H3 is highly expressed in patients with UC treated with adjuvant chemotherapy and it was associated with decreased recurrence-free survival and cancer-specific survival. Pending further validation in larger cohorts, B7-H3 expression may function as a predictor of response to adjuvant chemotherapy and thus be useful in patient and regimen selection. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation.
- Author
-
Takeuchi, Mitsuru, Froemming, Adam T., Kawashima, Akira, Thapa, Prabin, Carter, Rickey E., Cheville, John C., Thompson, R. Houston, and Takahashi, Naoki
- Subjects
RENAL cell carcinoma ,MAGNETIC resonance imaging ,CELL differentiation ,CANCER diagnosis ,TUMOR classification ,LYMPHADENITIS - Abstract
Purpose: The aim of the present study is to identify predictive imaging findings and construct a diagnostic model for differentiating renal cell carcinoma (RCC) with and without sarcomatoid dedifferentiation (sRCC and non-sRCC). Methods: This study is a single-center retrospective study. All patients had magnetic resonance imaging (MRI) with gradient-echo T1-weighted images, single-shot T2-weighted images (T2WI), and enhanced nephrographic phase images. Forty pathologically confirmed sRCCs and 80 non-sRCCs were included in this study. Control cases were selected by matching the tumor diameter and the year of MRI. Two radiologists independently evaluated the following findings: growth pattern, presence of low-intensity area on T2WI in the tumor (T2LIA), presence of non-enhancing area, local tumor stage, and presence of regional lymphadenopathy. Two radiologists measured the diameter of the tumor, T2LIA, and the non-enhancing area. Multivariable logistic regression analysis was used to identify independent predictive factors for differentiating sRCC from non-sRCC. Selected variables were entered in the logistic regression model, and the area under the curve (AUC) was calculated for each reader with 95% confidence intervals (CIs). Results: Larger T2LIA-to-tumor diameter ratio, regional lymphadenopathy, and local tumor stage 4 were associated with sRCC, and selected for the subsequent construction of a logistic regression model. With this model, the AUCs were 0.76 (95% CI, 0.66–0.85) and 0.70 (95% CI, 0.59–0.81) for prediction of sRCC. Conclusion: In conclusion, larger T2LIA-to-tumor diameter ratio, regional lymphadenopathy, and local tumor stage 4 are predictive findings of sRCC. As a result, the model constructed using these findings demonstrated a moderate degree of diagnostic accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. MP10-14 CONTEMPORARY ANALYSIS OF ONCOLOGICAL OUTCOMES OF RADICAL NEPHRECTOMY WITH VENOUS THROMBECTOMY FOR RENAL CELL CARCINOMA.
- Author
-
Basourakos, Spyridon P., Henning, Grant, Nabavizadeh, Reza, Pessoa, Rodrigo, Joyce, Daniel, Dorr, Madeline, Thompson, Houston, Boorjian, Stephen, Cheville, John C., Costello, Brian A., Leibovich, Bradley, and Sharma, Vidit
- Published
- 2024
- Full Text
- View/download PDF
15. A microRNA Transcriptome-wide Association Study of Prostate Cancer Risk.
- Author
-
Larson, Nicholas B., McDonnell, Shannon K., Fogarty, Zachary, Liu, Yuanhang, French, Amy J., Tillmans, Lori S., Cheville, John C., Wang, Liang, Schaid, Daniel J., and Thibodeau, Stephen N.
- Subjects
MICRORNA ,DISEASE risk factors ,NON-coding RNA ,MICRORNA genetics ,PROSTATE cancer - Abstract
Large genome-wide association studies have identified hundreds of single-nucleotide polymorphisms associated with increased risk of prostate cancer (PrCa), and many of these risk loci is presumed to confer regulatory effects on gene expression. While eQTL studies of long RNAs has yielded many potential risk genes, the relationship between PrCa risk genetics and microRNA expression dysregulation is understudied. We performed an microRNA transcriptome-wide association study of PrCa risk using small RNA sequencing and genome-wide genotyping data from N = 441 normal prostate epithelium tissue samples along with N = 411 prostate adenocarcinoma tumor samples from the Cancer Genome Atlas (TCGA). Genetically regulated expression prediction models were trained for all expressed microRNAs using the FUSION TWAS software. TWAS for PrCa risk was performed with both sets of models using single-SNP summary statistics from the recent PRACTICAL consortium PrCa case-control OncoArray GWAS meta-analysis. A total of 613 and 571 distinct expressed microRNAs were identified in the normal and tumor tissue datasets, respectively (overlap: 480). Among these, 79 (13%) normal tissue microRNAs demonstrated significant cis-heritability (median cis-h2 = 0.15, range: 0.03–0.79) for model training. Similar results were obtained from TCGA tumor samples, with 48 (9%) microRNA expression models successfully trained (median cis-h2 = 0.14, range: 0.06–0.60). Using normal tissue models, we identified two significant TWAS microRNA associations with PrCa risk: over-expression of mir-941 family microRNAs (P
TWAS = 2.9E-04) and reduced expression of miR-3617-5p (PTWAS = 1.0E-03). The TCGA tumor TWAS also identified a significant association with miR-941 overexpression (PTWAS = 9.7E-04). Subsequent finemapping of the TWAS results using a multi-tissue database indicated limited evidence of causal status for each microRNA with PrCa risk (posterior inclusion probabilities <0.05). Future work will examine downstream regulatory effects of microRNA dysregulation as well as microRNA-mediated risk mechanisms via competing endogenous RNA relationships. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
16. Large cell calcifying Sertoli cell tumour: a contemporary multi‐institutional case series highlighting the diagnostic utility of PRKAR1A immunohistochemistry.
- Author
-
Anderson, William J, Gordetsky, Jennifer B, Idrees, Muhammad T, Al‐Obaidy, Khaleel I, Kao, Chia‐Sui, Cornejo, Kristine M, Wobker, Sara E, Cheville, John C, Vargas, Sara O, Fletcher, Christopher D M, Hirsch, Michelle S, and Acosta, Andrés M
- Subjects
SERTOLI cells ,LEYDIG cells ,TUMORS ,IMMUNOHISTOCHEMISTRY ,SPERMATOGENESIS - Abstract
Aims: Large cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord‐stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC). Methods and results: The LCCSCT cohort (n = 15) had a median age of 16 years (range = 2–30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord‐stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression). Conclusions: Overall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features.
- Author
-
Rizzo, Natalie M., Sholl, Lynette M., Idrees, Muhammad T., Cheville, John C., Gupta, Sounak, Cornejo, Kristine M., Miyamoto, Hiroshi, Hirsch, Michelle S., Collins, Katrina, and Acosta, Andrés M.
- Published
- 2021
- Full Text
- View/download PDF
18. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
- Author
-
Davis Jr, John, Boughey, Judy C., Hoskin, Tanya L., Day, Courtney N., Cheville, John C., Piltin, Mara A., Hieken, Tina J., and Davis, John Jr
- Published
- 2021
- Full Text
- View/download PDF
19. Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma.
- Author
-
Bhindi, Bimal, Bearrick, Elizabeth N., Cheville, John C., Lohse, Christine M., Mason, Ross J., Shah, Paras, Harrington, Susan, Henan Zhang, Haidong Dong, Boorjian, Stephen A., Thompson, R. Houston, and Leibovich, Bradley C.
- Published
- 2021
- Full Text
- View/download PDF
20. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
- Author
-
Trpkov, Kiril, Hes, Ondrej, Williamson, Sean R., Adeniran, Adebowale J., Agaimy, Abbas, Alaghehbandan, Reza, Amin, Mahul B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Epstein, Jonathan I., Cheville, John C., Comperat, Eva, da Cunha, Isabela Werneck, Gordetsky, Jennifer B., Gupta, Sounak, He, Huiying, Hirsch, Michelle S., Humphrey, Peter A., and Kapur, Payal
- Published
- 2021
- Full Text
- View/download PDF
21. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.
- Author
-
Grassi, Tommaso, Harris, Faye R., Smadbeck, James B., Murphy, Stephen J., Block, Matthew S., Multinu, Francesco, Schaefer Klein, Janet L., Zhang, Piyan, Karagouga, Giannoula, Liu, Minetta C., Larish, Alyssa, Lemens, Maureen A., Sommerfield, Marla Kay S., Cappuccio, Serena, Cheville, John C., Vasmatzis, George, and Mariani, Andrea
- Subjects
CIRCULATING tumor DNA ,ENDOMETRIAL cancer ,ENDOMETRIAL tumors ,DNA ,CANCER patients ,CHROMOSOMAL rearrangement - Abstract
Introduction: There are no reliable blood biomarkers for monitoring endometrial cancer patients in the current clinical practice. Circulating tumor DNA (ctDNA) is emerging as a promising non-invasive method to measure tumor burden, define prognosis and monitor disease status in many solid cancers. In this pilot study, we investigated if unique tumor-specific DNA junctions can be used to detect ctDNA levels in patients with endometrial cancer. Methods: Chromosomal rearrangements in primary tumors of eleven patients with high-grade or advanced stage endometrial cancer were determined by whole-genome Mate-Pair sequencing. Identified unique tumor-specific junctions were evaluated in pre- and six-week post-surgery patient plasma using individualized quantitative polymerase chain reaction (qPCR) assays. The relationship between clinicopathological features and detection of ctDNA was investigated. Results: CtDNA was detected in 60% (6/10) of cases pre-surgery and in 27% (3/11) post-surgery. The detection of ctDNA pre-surgery was consistent with clinical indicators of aggressive disease such as advanced stage (80% - 4/5), lymphatic spread of disease (100% - 3/3), serous histology (80% - 4/5), deep myometrial invasion (100% - 3/3), lympho-vascular space invasion (75% - 3/4). All patients in which ctDNA was detected post-surgically had type II endometrial cancer. Discussion: This pilot study demonstrates the feasibility of using personalized tumor-specific junction panels for detecting ctDNA in the plasma of endometrial cancer patients. Larger studies and longer follow-up are needed to validate the potential association between pre-surgical ctDNA detection and the presence of cancers with aggressive pathologic tumor characteristics or advanced stage observed in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
- Author
-
Trpkov, Kiril, Williamson, Sean R., Gill, Anthony J., Adeniran, Adebowale J., Agaimy, Abbas, Alaghehbandan, Reza, Amin, Mahul B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Epstein, Jonathan I., Cheville, John C., Comperat, Eva, da Cunha, Isabela Werneck, Gordetsky, Jennifer B., Gupta, Sounak, He, Huiying, Hirsch, Michelle S., Humphrey, Peter A., and Kapur, Payal
- Published
- 2021
- Full Text
- View/download PDF
23. Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker.
- Author
-
Dubey, Divyanshu, Kryzer, Thomas, Guo, Yong, Clarkson, Benjamin, Cheville, John C., Costello, Brian A., Leibovich, Bradley C., Algeciras‐Schimnich, Alicia, Lucchinnetti, Claudia, Hammami, M. Bakri, Knight, Andrew M., Howe, Charles, Lennon, Vanda A., McKeon, Andrew, and Pittock, Sean J.
- Subjects
GERM cell tumors ,SEMINOMA ,LEUCINE zippers ,ENZYME-linked immunosorbent assay ,POSITRON emission tomography ,BIOMARKERS - Abstract
Objective: This study was undertaken to describe a novel biomarker of germ cell tumor and associated paraneoplastic neurological syndrome (PNS). Methods: Archival sera from patients with germ cell tumor–associated PNS were evaluated. We identified a common autoantigen in a human testicular cancer cell line (TCam‐2) by Western blot and mass spectrometry. Its identity was confirmed by recombinant‐protein Western blot, enzyme‐linked immunosorbent assay (ELISA), and cell‐based assay. Autoantibody specificity was confirmed by analyzing assorted control sera/cerebrospinal fluid. Results: Leucine zipper 4 (LUZP4)–immunoglobulin G (IgG) was detected in 28 patients' sera, 26 of whom (93%) were men. The median age at neurological symptom onset was 45 years (range = 28–84). Median titer (ELISA) was 1:300 (1:50 to >1:6,400, normal value < 1:50). Coexistent kelchlike protein 11–IgG was identified in 18 cases (64%). The most common presenting phenotype was rhombencephalitis (17/28, 61%). Other presentations included limbic encephalitis (n = 5, 18%), seizures and/or encephalitis (n = 2, 7%), and motor neuronopathy/polyradiculopathy (n = 4, 14%). The most common malignancy among cancer‐evaluated PNS patients was seminoma (21/27, 78%). Nine of the 21 seminomas detected by whole‐body fluorodeoxyglucose positron emission tomography scan (43%) were extratesticular. Both female patients had ovarian teratoma. Regressed testicular germ cell tumors were found in 4 patients. Exposure of T‐cell–dendritic‐cell cocultures from chronic immunosuppression‐naïve LUZP4‐IgG–seropositive patients to recombinant LUZP4 protein evoked a marked increase in CD69 expression on both CD4+ and CD8+ T cells when compared to vehicle‐exposed and healthy control cultures. Interpretation: LUZP4‐IgG represents a novel serological biomarker of PNS and has high predictive value for germ cell tumors. The demonstrated antigen‐specific T‐cell responses support a CD8+ T‐cell–mediated cytotoxic paraneoplastic and antitumor potential. ANN NEUROL 2021;89:1001–1010 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound.
- Author
-
Murphy, Stephen J., Levy, Michael J., Smadbeck, James B., Karagouga, Giannoula, McCune, Alexa F., Harris, Faye R., Udell, Julia B., Johnson, Sarah H., Kerr, Sarah E., Cheville, John C., Kipp, Benjamin R., Vasmatzis, George, and Gleeson, Ferga C.
- Subjects
ENDOSCOPIC ultrasonography ,CHROMOSOMAL rearrangement ,CHIMERIC proteins ,ANALYSIS of variance ,GENE rearrangement - Abstract
A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment‐naïve pancreatic cancers specimens obtained via endoscopic ultrasound (EUS). In many patients, this diagnostic biopsy procedure and specimen is the only opportunity to identify somatic clinically relevant actionable alterations that may impact their care and outcome. Specialized mate pair sequencing (MPseq) provided genome‐wide structural variance analysis (SVA) with a view to identifying prognostic markers and possible therapeutic targets. MPseq was successfully performed on all specimens, identifying highly rearranged genomes with complete SVA on all specimens with > 20% tumour content. SVA identified chimeric fusion proteins and potentially immunogenic readthrough transcripts, change of function truncations, gains and losses of key genes linked to tumour progression. Complex localized rearrangements, termed chromoanagenesis, with broad pattern heterogeneity were observed in 10 (83%) specimens, impacting multiple genes with diverse cellular functions that could influence theragnostic evaluation and responsiveness to immunotherapy regimens. This study indicates that genome‐wide MPseq can be successfully performed on very limited clinically EUS obtained specimens for chromosomal rearrangement detection and potential theragnostic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Primary Female Urethral Carcinoma: Proposed Staging Modifications Based on Assessment of Female Urethral Histology and Analysis of a Large Series of Female Urethral Carcinomas.
- Author
-
Aron, Manju, Park, Sanghui, Lowenthal, Brett M., Gupta, Sounak, Sahoo, Debashis, Cheville, John C., and Hansel, Donna E.
- Published
- 2020
- Full Text
- View/download PDF
26. Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery.
- Author
-
Racz, Jennifer M., Glasgow, Amy E., Keeney, Gary L., Degnim, Amy C., Hieken, Tina J., Jakub, James W., Cheville, John C., Habermann, Elizabeth B., and Boughey, Judy C.
- Abstract
Background: Reoperation rates following breast-conserving surgery (BCS) range from 10 to 40%, with marked surgeon and institutional variation. Objective: The aim of this study was to identify factors associated with intraoperative margin re-excision, evaluate for any differences in local recurrence based on margin re-excision and determine reoperation rates with use of intraoperative margin analysis. Patients and Methods: We analyzed consecutive patients with ductal carcinoma in situ (DCIS) or invasive breast cancer who underwent BCS at our institution between 1 January 2005 and 31 December 2016. Routine intraoperative frozen section margin analysis was performed and positive or close margins were re-excised intraoperatively. Univariate analysis was used to compare margin status and the Kaplan–Meier method was used to compare recurrence. Multivariable logistic regression was utilized to analyze factors associated with re-excision. Results: We identified 3201 patients who underwent BCS—688 for DCIS and 2513 for invasive carcinoma. Overall, 1513 (60.2%) patients with invasive cancer and 434 (63.1%) patients with DCIS had close or positive margins that underwent intraoperative re-excision. Margin re-excision was associated with larger tumor size in both groups. The permanent pathology positive margin rate among all patients was 1.2%, and the 30-day reoperation rate for positive margins was 1.1%. Five-year local recurrence rates were 0.6% and 1.2% for patients with DCIS and invasive cancer, respectively. There was no difference in recurrence between patients with and without intraoperative margin re-excision (p = 0.92). Conclusion: Both DCIS and invasive carcinoma had similar rates of intraoperative margin re-excision. Although intraoperative margin re-excision was common, the reoperation rate was extremely low and there was no difference in recurrence between those with or without intraoperative re-excision. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Diffuse Pulmonary Meningotheliomatosis: A Rare Lung Disease Presenting with Diffuse Ground-Glass Opacities and Cavitation.
- Author
-
Alkurashi, Adham K., Almodallal, Yahya, Albitar, Hasan Ahmad Hasan, Cheville, John C., and Iyer, Vivek N.
- Subjects
LUNG diseases ,RARE diseases ,SYMPTOMS ,PULMONARY nodules ,ETIOLOGY of diseases ,INTERSTITIAL lung diseases - Abstract
Objective: Rare disease. Background: Diffuse pulmonary meningotheliomatosis (DPM) is an exceedingly rare diffuse pulmonary disease with a female predominance. It is characterized by the presence of widespread bilateral minute pulmonary meningotheliallike nodules (MPMNs) on chest imaging. Patients are generally asymptomatic or may present with nonspecific symptoms such as dyspnea. The nodules are typically detected incidentally on imaging for other indications. Here, we present a rare case of DPM in a 55-year-old woman. Case Report: A 55-year-old woman presented to the clinic with non-exertional chest pressure and dry cough of 4-month duration. She had a history of hypertension, hypercholesterolemia, hypothyroidism, gastroesophageal reflux disease, and impaired fasting blood glucose and was a lifelong nonsmoker. Physical examination was unremarkable. High-resolution chest computed tomography (CT) showed innumerable diffuse small ground-glass nodules. An extensive laboratory workup was negative for autoimmune and infectious etiologies. The patient underwent uncomplicated right video-assisted thoracoscopic surgery, and lung biopsy showed multiple wellcircumscribed interstitial meningothelial-like nodules in perivenular distribution with occasional whorling of cells. The diagnosis of diffuse pulmonary meningotheliomatosis (DPM) was confirmed. The patient continued to complain of non-exertional chest pressure without pulmonary complaints, and a repeat chest CT showed stable findings 1 year after the diagnosis. Conclusions: DPM should be considered in the differential diagnosis for patients presenting with diffuse bilateral pulmonary nodules. Patients are typically asymptomatic and it is most commonly detected incidentally. Further research is needed to better understand this disease and its clinical significance. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy.
- Author
-
Yang, David Y, Potretzke, Theodora A, Miest, Tanner S, Bhindi, Bimal, Lohse, Christine M, Cheville, John C, King, Bernard F, Boorjian, Stephen A, Leibovich, Bradley C, Thompson, R Houston, and Potretzke, Aaron M
- Subjects
RENAL cell carcinoma ,LIVER metastasis ,BONES ,LYMPH nodes - Abstract
Objectives: To evaluate the timing and distribution of first renal cell carcinoma metastasis after nephrectomy stratified by nodal status. Methods: We evaluated patients treated with nephrectomy for sporadic, unilateral renal cell carcinoma between 1970 and 2011 who subsequently developed distant metastasis to three or fewer sites. Site‐specific metastases‐free 2‐year survival rates were estimated using the Kaplan–Meier method. Associations of nodal status with time to metastasis were evaluated using multivariable Cox regression models. Results: A total of 1049 patients met the inclusion criteria (135 pN1, 914 pN0/x patients). The median time to identification of first distant metastasis for pN1 patients was 0.4 years (interquartile range 0.2–1.1 years) versus 2.2 years (interquartile range 0.6–6.0 years) in pN0/x patients. The most common site of metastasis was to the lung, but this occurred earlier in pN1 patients (median 0.3 years vs 2.0 years). pN1 was associated with significantly lower site‐specific 2‐year metastases‐free survival when compared with pN0/x for lung (37% vs 70%, P < 0.001), bone (63% vs 87%, P < 0.001), non‐regional lymph nodes (60% vs 96%, P < 0.001) and liver metastases (79% vs 91%, P < 0.001). On multivariable analysis, pN1 status remained significantly associated with lung, bone, and non‐regional lymph node (all P < 0.001) metastases, but it was no longer associated with liver metastases (P = 0.3). Conclusions: pN1 nodal status in M0 patients treated with nephrectomy for renal cell carcinoma is associated with more frequent early metastasis to sites conferring poor prognosis when compared with pN0/x. Our findings highlight the importance of rigorous, early surveillance though the multimodal use of a comprehensive history, physical, laboratory and radiological studies, as outlined in societal guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
- Author
-
Gandhi, Jatin S., Smith, Steven C., Paner, Gladell P., McKenney, Jesse K., Sekhri, Radhika, Osunkoya, Adeboye O., Baras, Alexander S., DeMarzo, Angelo M., Cheville, John C., Rafael, Jiminez E., Trpkov, Kiril, Colecchia, Maurizio, Ro, Jae Y., Montironi, Rodolfo, Menon, Santosh, Hes, Ondrej, Williamson, Sean R., Hirsch, Michelle S., Netto, George J., and Fine, Samson W.
- Published
- 2020
- Full Text
- View/download PDF
30. Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma.
- Author
-
Eckel‐Passow, Jeanette E., Ho, Thai H., Serie, Daniel J., Cheville, John C., Houston Thompson, R., Costello, Brian A., Dong, Haidong, Kwon, Eugene D., Leibovich, Bradley C., and Parker, Alexander S.
- Subjects
RENAL cell carcinoma ,PROGRAMMED cell death 1 receptors ,PROGRAMMED death-ligand 1 ,METASTASIS - Abstract
Objectives: Previous studies noted discordance of programmed death‐1 (PD‐1) and one of its ligands (PD‐L1) across patient‐matched primary and metastatic clear cell renal cell carcinoma (ccRCC). There are inconsistencies if the primary or metastatic tumor has higher expression, and whether metastatic tumor expression is associated with patient outcome. Thus, we examined PD‐1 and PD‐L1 in patient‐matched tumors using a large number of ccRCC patients with long follow‐up. Materials and Methods: We analyzed PD‐1 and PD‐L1 using immunohistochemistry in patient‐matched primary and metastatic tumors from 110 ccRCC patients. Concordance was assessed among longitudinal metastatic tumors, as well as across patient‐matched primary and metastatic tumors. Cox proportional hazards regression was used to evaluate the associations of metastatic tumor expression with cancer‐specific survival. Results: We observed inter‐metastatic tumor heterogeneity of PD‐1 in 25 (69%) of the 36 patients and of PD‐L1 in seven (19%) patients. Concordance between patient‐matched primary and metastatic tumors was 73% (Kappa = 0.16, 95% CI: −0.003‐0.32). Similarly, concordance of PD‐L1 between metastatic and patient‐matched primary tumors was 78% (Kappa = 0.27, 95% CI: 0.09‐0.46). Both markers demonstrated higher expression in primary vs metastatic tumors. Metastatic tumor expression of PD‐1 was significantly associated with metastatic location (P <.0001) and ccRCC‐specific survival (HR = 2.15, 95% CI: 1.06‐4.36, P =.035). Conclusions: The expression of PD‐1 and PD‐L1 is discordant across patient‐matched ccRCC tumors, with higher expression in primary tumors. Higher PD‐1 expression was associated with metastatic location and lower cancer‐specific survival. If validated, these results highlight the importance of evaluating these biomarkers in metastatic tissue specifically. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
- Author
-
Boeri, Luca, Soligo, Matteo, Frank, Igor, Boorjian, Stephen A., Thompson, R. Houston, Tollefson, Matthew, Tarrel, Robert, Quevedo, Fernando J., Cheville, John C., and Karnes, R. Jeffrey
- Subjects
CYSTECTOMY ,BLADDER cancer ,PROPENSITY score matching ,LOGISTIC regression analysis ,PROGNOSIS ,CANCER chemotherapy - Abstract
Purpose: To investigate the prevalence of and factors' association with receiving suboptimal neoadjuvant chemotherapy (NAC) and its impact on survival outcomes in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy (RC). Methods: We reviewed 1119 patients treated with NAC and/or RC for cT2-cT4N0M0 BC. Patients were segregated into three groups: (i) suboptimal NAC (received < 3 cycles of cisplatin-based NAC or non-cisplatin-based regimen), (ii) optimal NAC and (iii) no NAC. Clinical characteristics were compared among groups. Logistic regression analyses tested the association between clinical variables and the odds of receiving suboptimal NAC. To adjust for potential baseline confounders, propensity score matching was performed. Pathologic outcomes were compared between groups and Cox regression analyses tested the risk factors associated with recurrence, overall (OM) and cancer-specific mortality (CSM). Results: Before matching, 84/315 (26.6%) patients received a suboptimal NAC regimen. Lower general health status and impaired renal functions were the most significant factors associated with the administration of a suboptimal NAC. After matching, the optimal NAC group achieved higher rates of complete pathological response as compared to the suboptimal group (p = 0.03). Suboptimal NAC (HR 1.77; p = 0.015) and no NAC (HR 1.52; p = 0.03) were both associated with higher risk of recurrence and OM (HR 1.71; p = 0.02 and HR 1.61; p = 0.02) as compared to optimal NAC. Conclusion: One out of four MIBC patients received a suboptimal NAC regimen before RC. Receiving a suboptimal NAC regimen was associated with worse disease recurrence and survival outcomes following surgery, as compared to an optimal NAC regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Fumarate Hydratase (FH) c.1431_1433dupAAA (p.Lys477dup) variant is not associated with FH protein deficiency and increased 2SC in two separate patients with renal neoplasia.
- Author
-
Gupta, Sounak, Shen, Wei, Jimenez, Rafael E., and Cheville, John C.
- Published
- 2021
- Full Text
- View/download PDF
33. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
- Author
-
Gupta, Sounak, Cheville, John C., Jungbluth, Achim A., Zhang, Yanming, Zhang, Lei, Chen, Ying-Bei, Tickoo, Satish K., Fine, Samson W., Gopalan, Anuradha, Al-Ahmadie, Hikmat A., Sirintrapun, Sahussapont J., Blum, Kyle A., Lohse, Christine M., Hakimi, A. Ari, Thompson, R. Houston, Leibovich, Bradley C., Berger, Michael F., Arcila, Maria E., Ross, Dara S., and Ladanyi, Marc
- Published
- 2019
- Full Text
- View/download PDF
34. A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.
- Author
-
Lyon, Timothy D., Frank, Igor, Sharma, Vidit, Shah, Paras H., Tollefson, Matthew K., Thompson, R. Houston, Karnes, R. Jeffrey, Thapa, Prabin, Cheville, John C., and Boorjian, Stephen A.
- Subjects
BLADDER cancer ,CANCER patients - Abstract
Purpose: To validate published risk criteria for informing use of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC), and to examine outcomes of low-risk (LR) patients treated with immediate radical cystectomy (RC). Methods: We identified 1931 patients who underwent RC for MIBC from 1980 to 2016. Patients were considered high risk (HR) with hydronephrosis, lymphovascular invasion, variant histology and/or cT3/4 disease. Kaplan–Meier survival estimates were compared to patients classified as LR, and logistic regression was used to examine factors associated with pathologic downstaging. Results: A total of 1025 LR and 906 HR patients were identified. Median follow-up was 6.3 years (IQR 2.6–12), during which time 1321 (68%) patients died, 753 (39%) from bladder cancer. HR patients had significantly lower 5-year CSS than LR patients (50% vs. 68%, p = 0.001). Of 561 cisplatin-eligible LR patients treated with RC without NAC, 293 (52%) had pathologic non-organ confined disease; of these, 81 (14%) received adjuvant chemotherapy; 78 (14%) did not due to a perioperative event, while 134 (24%) did not due to patient/provider choice. NAC in LR patients was associated with greater odds of pT0 (OR 3.05; p < 0.001) and < pT2 (OR 2.53; p < 0.001) disease, but was not significantly associated with CSS (p = 0.31). Conclusions: Our results validate the proposed risk groups. Among LR patients treated without NAC, 52% experienced pathologic upstaging, and 14% were unable to receive adjuvant chemotherapy due to a perioperative event. These data support offering NAC to both HR and LR MIBC patients, and may be useful for patient counseling. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle‐invasive bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy and radical cystectomy: a single‐centre experience
- Author
-
Boeri, Luca, Soligo, Matteo, Frank, Igor, Boorjian, Stephen A., Thompson, Robert H., Tollefson, Matthew, Quevedo, Fernando J., Cheville, John C., and Karnes, Robert Jeffrey
- Subjects
CIGARETTE smoke ,BLADDER cancer patients ,DISEASE relapse ,BLADDER cancer ,BLADDER injuries ,LOGISTIC regression analysis ,CYSTECTOMY - Abstract
Objective: To investigate the association between smoking status and pathological response to cisplatin‐based neoadjuvant chemotherapy (NAC) and survival outcomes in patients with muscle‐invasive bladder cancer (MIBC) treated with radical cystectomy (RC). Patients and Methods: We reviewed 201 patients treated with NAC and RC for cT2–cT4N0M0 BC between 01/1999 and 01/2015. Smoking status was categorised as: 'never', 'former', and 'current' smoker. Pathological response to NAC was defined as: complete (ypT0N0), partial (ypTis/Ta/T1, N0), and no response (ypT2–4 or ypN+). Clinicopathological characteristics were analysed according to smoking status. Logistic regression analyses tested the association between smoking status and pathological response to NAC. Cox regression analyses tested risk factors associated with recurrence, overall (OM) and cancer‐specific mortality (CSM). Results: Overall, there were 58 (28.9%) never smokers, 87 (43.3%) former smokers, and 56 (27.9%) current smokers. No response to NAC was more frequently noted in current smokers (73.2%; P = 0.007). Former smoker (odds ratio [OR] 2.28; P = 0.024) and current smoker statuses (OR 4.52; P < 0.001) were significantly associated with no response to NAC, after adjusting for age, gender, Charlson Comorbidity Index, and clinical stage. Similarly, current smoking status (hazard ratio [HR] 2.14; P = 0.03) and extravesical pathological tumour stage (HR 3.31; P < 0.001) were independently associated with an increased risk of recurrence after RC. Conclusion: Cigarette smoking was significantly associated with adverse pathological response to cisplatin‐based NAC in patients with MIBC treated with RC. Current smokers were at significantly higher risk of disease recurrence as compared to former and never smokers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set.
- Author
-
DeRycke, Melissa S., Larson, Melissa C., Nair, Asha A., McDonnell, Shannon K., French, Amy J., Tillmans, Lori S., Riska, Shaun M., Baheti, Saurabh, Fogarty, Zachary C., Larson, Nicholas B., O’Brien, Daniel R., Cheville, John C., Wang, Liang, Schaid, Daniel J., and Thibodeau, Stephen N.
- Subjects
EXOCRINE glands ,CANCER genes ,PROSTATE cancer ,GENE expression ,NUCLEOTIDE sequence ,NON-coding RNA - Abstract
Prostate cancer (PrCa) is highly heritable; 284 variants have been identified to date that are associated with increased prostate cancer risk, yet few genes contributing to its development are known. Expression quantitative trait loci (eQTL) studies link variants with affected genes, helping to determine how these variants might regulate gene expression and may influence prostate cancer risk. In the current study, we performed eQTL analysis on 471 normal prostate epithelium samples and 249 PrCa-risk variants in 196 risk loci, utilizing RNA sequencing transcriptome data based on ENSEMBL gene definition and genome-wide variant data. We identified a total of 213 genes associated with known PrCa-risk variants, including 141 protein-coding genes, 16 lncRNAs, and 56 other non-coding RNA species with differential expression. Compared to our previous analysis, where RefSeq was used for gene annotation, we identified an additional 130 expressed genes associated with known PrCa-risk variants. We detected an eQTL signal for more than half (n = 102, 52%) of the 196 loci tested; 52 (51%) of which were a Group 1 signal, indicating high linkage disequilibrium (LD) between the peak eQTL variant and the PrCa-risk variant (r
2 >0.5) and may help explain how risk variants influence the development of prostate cancer. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
37. Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear‐cell renal cell carcinoma.
- Author
-
Shah, Paras H., Lyon, Timothy D., Lohse, Christine M., Cheville, John C., Leibovich, Bradley C., Boorjian, Stephen A., and Thompson, R. Houston
- Subjects
RENAL veins ,RENAL cell carcinoma ,CANCER prognosis ,NEPHRECTOMY ,TUMORS - Abstract
Objective: To investigate the prognostic significance of various patterns of extrarenal extension that comprise pathological stage T3a clear‐cell renal cell carcinoma (ccRCC) amongst patients undergoing nephrectomy for non‐metastatic disease. Patients and Methods: A retrospective review of 563 patients who underwent radical nephrectomy for pathologically confirmed T3aN0/NxM0 ccRCC between 1970 and 2011 was performed. All pathological slides were re‐reviewed by one urological pathologist. Associations of patterns of extrarenal extension (perinephric fat [PF], renal sinus fat [SF], and renal vein [RV], in isolation or in any combination) with disease progression, cancer‐specific mortality (CSM), and all‐cause mortality were evaluated on multivariable analyses. Results: Overall, PF invasion, renal SF invasion, and RV tumour thrombus were present in 144 (26%), 51 (9%), and 163 (29%) patients, respectively, with multiple patterns of extrarenal extension identified in 205 (36%) patients. There were no significant differences in survival outcomes for isolated involvement of PF, renal SF, or RV. However, patients with multiple patterns of extrarenal extension were at significantly increased risk of disease progression (hazard ratio [HR] 1.31, 95% confidence interval [CI] 1.04–1.65; P = 0.020), CSM (HR 1.64, 95% CI 1.27–2.12; P < 0.001), and all‐cause mortality (HR 1.32, 95% CI 1.08–1.61; P = 0.008). Conclusions: The presence of multiple patterns of extrarenal extension is associated with a higher risk of disease progression and cancer‐related death after radical nephrectomy compared to isolated involvement of the PF, renal SF, or RV, which carry similar prognostic weight. If validated, these findings may help refine risk stratification of non‐metastatic T3a RCC by distinguishing patients with multiple vs one pattern of extrarenal extension. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. The Association of Aspirin Use with Survival Following Radical Cystectomy.
- Author
-
Lyon, Timothy D., Frank, Igor, Shah, Paras H., Tarrell, Robert, Cheville, John C., Karnes, R. Jeffrey, Thompson, R. Houston, Tollefson, Matthew K., and Boorjian, Stephen A.
- Published
- 2018
- Full Text
- View/download PDF
39. Defining clear cell papillary renal cell carcinoma in routine clinical practice.
- Author
-
Gupta, Sounak, Inwards, Carrie Y, Van Dyke, Daniel L, Jimenez, Rafael E, and Cheville, John C
- Subjects
RENAL cell carcinoma ,P16 gene - Abstract
Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from The Cancer Genome Atlas database. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
40. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
- Author
-
Gupta, Sounak, Sahu, Divya, Bomalaski, John S., Frank, Igor, Boorjian, Stephen A., Thapa, Prabin, Cheville, John C., and Hansel, Donna E.
- Abstract
High-grade neuroendocrine carcinomas (HGNECs) of the urinary bladder encompass small cell (SCNEC) and large cell neuroendocrine carcinomas (LCNEC). Currently, recommended initial management is with systemic chemotherapy, followed by consolidative therapy with either radical cystectomy or radiotherapy in patients with localized disease. Nevertheless, survival in this setting remains poor. We therefore evaluated the potential to modify arginine metabolism as an alternative, targeted therapy approach in these carcinomas. In humans, arginine is a semi-essential amino acid and its synthesis enzyme argininosuccinate synthetase (ASS1) represents the rate-limiting step in arginine biosynthesis. Neoplasms that show low to absent ASS1 expression require extracellular arginine for cancer cell survival, and thus can be targeted using arginine-degrading enzymes such as pegylated arginine deiminase (ADI-PEG 20). An initial study by our group of 19 patients demonstrated that a high percentage of SCNEC lack ASS1 expression. Herein, we evaluated an expanded cohort of 74 radical cystectomy patients with HGNEC, including 63 SCNEC, 5 LCNEC, and 6 mixed morphology HGNEC patients. ASS1 expression was assessed through immunohistochemistry. Fifty-eight (of 74, 78%) patients with HGNEC showed absent ASS1 expression, including all patients with LCNEC and mixed morphology (11 of 11, 100%). Ten-year survival from disease-specific death was not statistically significant between ASS1-expressing and ASS1-deficient cases (p = 0.75). Our results show that HGNEC of the bladder may be candidates for arginine deprivation therapy using drugs such as ADI-PEG 20. Further studies are needed to validate these findings and to determine the therapeutic efficacy of such agents. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
- Author
-
Gearman, Derek J., Morlacco, Alessandro, Cheville, John C., Rangel, Laureano J., and Karnes, R. Jeffrey
- Published
- 2018
- Full Text
- View/download PDF
42. Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis.
- Author
-
Gershman, Boris, Thompson, R. Houston, Boorjian, Stephen A., Larcher, Alessandro, Capitanio, Umberto, Montorsi, Francesco, Carenzi, Cristina, Bertini, Roberto, Briganti, Alberto, Lohse, Christine M., Cheville, John C., and Leibovich, Bradley C.
- Published
- 2018
- Full Text
- View/download PDF
43. Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma.
- Author
-
Antwi, Samuel O., Eckel-Passow, Jeanette E., Diehl, Nancy D., Serie, Daniel J., Custer, Kaitlynn M., Wu, Kevin J., Cheville, John C., Thiel, David D., Leibovich, Bradley C., and Parker, Alexander S.
- Abstract
Alcohol consumption has been associated inversely with renal cell carcinoma (RCC) risk; however, no study has examined effect modification by germline variation in alcohol-metabolizing genes. We investigated whether the association between alcohol intake and RCC risk is modulated by germline variants in alcohol dehydrogenase genes in a large case-control study. Data from 652 RCC cases and 1,366 non-cancer controls were analyzed. Alcohol intake was assessed using a standardized risk factor questionnaire. Three previously genotyped polymorphisms in ADH6 and ADH7 with the TaqMan assay were examined. Odds ratios (ORs) and 95% confidence interval (CI) were calculated using logistic regression, adjusting for covariates. Compared to nondrinkers, ever consumption of alcohol was associated with lower RCC risk (OR = 0.52, 95% CI = 0.42-0.65). Analysis with cubic spline regression curve showed a "J-shaped" relationship between alcohol drinks/day and RCC risk, such that there was no added benefit against RCC for consumption of more than two drinks/day. We observed effect modification by variation in rs1154454 (ADH7) (PmteracUon = 0.007); a per unit increase in alcohol drink/day was associated with 35% lower RCC risk among non-minor allele carriers, a 27% lower risk among those who carry one copy of the minor allele, but no association was observed among those with two copies of the minor allele. These findings indicate that alcohol consumption is associated with lower RCC risk. Consuming more than two drinks a day does not confer additional protection against RCC. The association between alcohol intake and RCC risk appears to be modulated by inter-individual germline variation in alcohol-metabolizing genes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.
- Author
-
Giridhar, Karthik V., Sosa, Carlos P., Hillman, David W., Sanhueza, Cristobal, Dalpiaz, Candace L., Costello, Brian A., Quevedo, Fernando J., Pitot, Henry C., Dronca, Roxana S., Ertz, Donna, Cheville, John C., Donkena, Krishna Vanaja, and Kohli, Manish
- Subjects
MESSENGER RNA ,RENAL cell carcinoma ,GENE expression ,METASTASIS ,TUMORS - Abstract
The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. We analyzed whole blood mRNA expression in metastatic clear cell renal cell carcinoma (mCCRCC) patients and compared it to the MSKCC score for predicting overall survival. In a discovery set of 19 patients with mRCC, we performed whole transcriptome RNA sequencing and selected eighteen candidate genes for further evaluation based on associations with overall survival and statistical significance. In an independent validation of set of 47 patients with mCCRCC, transcript expression of the 18 candidate genes were quantified using a customized NanoString probeset. Cox regression multivariate analysis confirmed that two of the candidate genes were significantly associated with overall survival. Higher expression of BAG1 [hazard ratio (HR) of 0.14, p < 0.0001, 95% confidence interval (CI) 0.04-0.36] and NOP56 (HR 0.13, p < 0.0001, 95% CI 0.05-0.34) were associated with better prognosis. A prognostic model incorporating expression of BAG1 and NOP56 into the MSKCC score improved prognostication significantly over a model using the MSKCC prognostic score only (p < 0.0001). Prognostic value of using whole blood mRNA gene profiling in mCCRCC is feasible and should be prospectively confirmed in larger studies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
45. Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy.
- Author
-
Yang, David Y., Thompson, R. Houston, Zaid, Harras B., Lohse, Christine M., Rule, Andrew D., Boorjian, Stephen A., Leibovich, Bradley C., Cheville, John C., and Tollefson, Matthew K.
- Published
- 2017
- Full Text
- View/download PDF
46. Coffee consumption and risk of renal cell carcinoma.
- Author
-
Antwi, Samuel, Eckel-Passow, Jeanette, Diehl, Nancy, Serie, Daniel, Custer, Kaitlynn, Arnold, Michelle, Wu, Kevin, Cheville, John, Thiel, David, Leibovich, Bradley, Parker, Alexander, Antwi, Samuel O, Eckel-Passow, Jeanette E, Diehl, Nancy D, Serie, Daniel J, Custer, Kaitlynn M, Arnold, Michelle L, Wu, Kevin J, Cheville, John C, and Thiel, David D
- Subjects
CAFFEINE ,COFFEE ,KIDNEY tumors ,LONGITUDINAL method ,RENAL cell carcinoma ,LOGISTIC regression analysis ,CASE-control method ,ODDS ratio - Abstract
Background: Studies have suggested an inverse association between coffee consumption and risk of renal cell carcinoma (RCC); however, data regarding decaffeinated coffee are limited.Methods: We conducted a case-control study of 669 incident RCC cases and 1,001 frequency-matched controls. Participants completed identical risk factor questionnaires that solicited information about usual coffee consumption habits. The study participants were categorized as non-coffee, caffeinated coffee, decaffeinated coffee, or both caffeinated and decaffeinated coffee drinkers. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression, adjusting for multiple risk factors for RCC.Results: Compared with no coffee consumption, we found an inverse association between caffeinated coffee consumption and RCC risk (OR 0.74; 95% CI 0.57-0.99), whereas we observed a trend toward increased risk of RCC for consumption of decaffeinated coffee (OR 1.47; 95% CI 0.98-2.19). Decaffeinated coffee consumption was associated also with increased risk of the clear cell RCC (ccRCC) subtype, particularly the aggressive form of ccRCC (OR 1.80; 95% CI 1.01-3.22).Conclusions: Consumption of caffeinated coffee is associated with reduced risk of RCC, while decaffeinated coffee consumption is associated with an increase in risk of aggressive ccRCC. Further inquiry is warranted in large prospective studies and should include assessment of dose-response associations. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
47. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
- Author
-
Gupta, Sounak, Johnson, Sarah H, Vasmatzis, George, Porath, Binu, Rustin, Jeannette G, Rao, Priya, Costello, Brian A, Leibovich, Bradley C, Thompson, R Houston, Cheville, John C, and Sukov, William R
- Published
- 2017
- Full Text
- View/download PDF
48. Genomic tests to guide prostate cancer management following diagnosis.
- Author
-
Colicchia, Michele, Morlacco, Alessandro, Cheville, John C., and Karnes, R. Jeffrey
- Abstract
Introduction: Prostate cancer (PCa) is a common cancer in men, but variable clinical behaviors make its management challenging. Risk stratification is a key issue in disease management. Patient-tailored strategies are strongly advocated to reduce unnecessary treatment while maximizing the oncological outcomes of patient who need active treatment in the primary, adjuvant or salvage setting. Recently, tissue-based biomarkers or genomic tests have become available to improve the clinical decision-making. Areas covered: In this review, the authors present recent evidence about these tissue-based biomarkers, discussing the application of each of them in the clinical setting, focusing on the tests aimed to provide a better risk stratification and to guide decision-making after the diagnosis of PCa (i.e. OncotypeDXⓇ, ProlarisⓇ, ProMarkⓇ, Ki-67, DecipherⓇ, PTEN, PORTOS, AR-V7 and DNA repair gene mutations). Expert commentary: Even if the clinicopathologic features are still the most frequently-used predictors of disease progression, these tools can be helpful in decision-making at every stage of the PCa management. Actually, OncotypeDXⓇ, ProlarisⓇand DecipherⓇare recommended in the clinical setting by guidelines at different steps of PCa management. Consequently, further studies are indispensable to better tailor the right therapy for the right patient and at the right time. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
49. Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma.
- Author
-
Bailey, George C., Boorjian, Stephen A., Ziegelmann, Matthew J., Westerman, Mary E., Lohse, Christine M., Leibovich, Bradley C., Cheville, John C., and Thompson, R. Houston
- Subjects
RENAL cell carcinoma ,CANCER invasiveness ,SURVIVAL analysis (Biometry) ,FOLLOW-up studies (Medicine) ,NEPHRECTOMY ,PROGNOSIS - Abstract
Objectives To evaluate the prognostic significance of urinary collecting system invasion ( UCSI) in a large series of patients with clear-cell renal cell carcinoma ( RCC). Materials and Methods Patients with clear-cell RCC treated with nephrectomy between 2001 and 2010 were reviewed from a prospectively maintained registry. One urological pathologist re-reviewed all slides. Cancer-specific survival was estimated using the Kaplan-Meier method, and associations of UCSI with death from RCC were evaluated using Cox models. Results Of the 859 patients with clear-cell RCC, 58 (6.8%) had UCSI. At last follow-up, 310 patients had died from RCC at a median of 1.8 years after surgery. The median follow-up for patients alive at last follow-up was 8.2 years. The estimated cancer-specific survival at 10 years after surgery for patients with UCSI was 17%, compared with 60% for patients without UCSI ( P < 0.001). In a multivariable model, UCSI remained independently associated with an increased risk of death from RCC (hazard ratio 1.5; P = 0.018). Further, among patients with pT3 RCC, those with USCI had survival outcomes similar to those of patients with pT4 RCC. Conclusions Collecting system invasion is associated with poor prognosis among patients with clear-cell RCC. If validated, consideration should be given to including UCSI in future staging systems. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
- Author
-
Eckel-Passow, Jeanette E., Serie, Daniel J., Cheville, John C., Ho, Thai H., Kapur, Payal, Brugarolas, James, Houston Thompson, R., Leibovich, Bradley C., Kwon, Eugene D., Joseph, Richard W., Parker, Alexander S., and Thompson, R Houston
- Subjects
RENAL cell carcinoma ,TUMOR diagnosis ,PROTEIN expression ,IMMUNOHISTOCHEMISTRY ,CHROMATIN ,PATIENTS - Abstract
Background: BAP1 and PBRM1 are frequently mutated in primary clear cell renal cell carcinoma (ccRCC) tumors; however, the frequency and clinical relevance of these mutations in metastatic ccRCC tumors is unknown. Additionally, while intra-tumor heterogeneity has been shown to be common in primary ccRCC, little is known regarding heterogeneity in metastatic ccRCC tumors.Materials and Methods: We analyzed BAP1 and PBRM1 loss of protein expression in patient-matched primary and metastatic tumors from 97 patients. Expression was determined using a validated immunohistochemistry assay, which has been shown to be correlated with mutation status.Results: Of the 97 patients evaluated, 20 and 57% showed loss of BAP1 and PBRM1 in their primary tumors, respectively. Comparing expression across patient-matched primary-metastatic tumor pairs, 98 and 90% had concordant BAP1 and PBRM1 expression, respectively. Both patients who demonstrated discordant BAP1 expression showed loss of BAP1 expression during progression to metastatic ccRCC. Similarly, seven of the ten patients that demonstrated discordant PBRM1 expression showed loss of PBRM1 expression during progression to metastatic ccRCC. We evaluated intra-metastatic tumor heterogeneity using 12 patients who had multiple blocks available from the same tumor with representative pathology; 100 and 92% showed concordant BAP1 and PBRM1 expression, respectively. Amongst 32 patients who had serial metastatic tumors available, both BAP1 and PBRM1 had 97% concordant expression.Conclusions: We observed minimal intra- and inter- tumor heterogeneity in metastatic ccRCC tumors. Patients with discordant BAP1 or PBRM1 expression across their matched primary and metastatic tumors usually showed loss of expression during progression to metastatic ccRCC. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.